As part of the Cancer Moonshot, representatives from government, academic, pharmaceutical and diagnostic companies are launching a new partnership in pursuit of creating an open database for liquid biopsies to potentially accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit.
The University of Michigan Comprehensive Cancer Center is one of 12 sites to joinPrecision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
One of the most common cancer-causing genes has continuously stymied researchers’ efforts to develop treatments against it. Now, researchers have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer.
Researchers found that only 55 percent of colorectal cancer patients who were employed at the time of diagnosis retained their jobs after treatment. Patients who had paid sick leave were nearly twice as likely to retain their jobs as those without paid sick leave.
Researchers at the University of Michigan have identified a potential new approach to fertility preservation for young cancer patients that addresses concerns about beginning cancer treatment immediately and the possibility of reintroducing cancer cells during the fertility preservation process.
When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations. The findings could have significant implications for treatment recommendations.
A new study from the University of Michigan Comprehensive Cancer Center reveals molecular changes within a tumor that are preventing immunotherapy drugs from killing off the cancer. It explains why not all patients respond to immunotherapy treatments.
A survey of women with breast cancer found that nearly half considered having a double mastectomy. But of those who considered it, only 37 percent knew that the more aggressive procedure does not improve survival for women with breast cancer.
In a major advance in precision medicine, an international collaboration of researchers found 90 percent of castration resistant metastatic prostate cancers harbored some kind of genetic anomaly that could drive treatment choices.
Why do some cancer cells break away from a tumor and travel to distant parts of the body? A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
A new urine-based test improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
The Centers for Medicare and Medicaid Services have finalized coverage guidelines for lung cancer screening with CT scans for people at high-risk of developing lung cancer. Coverage goes into effect immediately.